accounta lack of therapeutic options for people.��� Elan���s new chairman Bob Ingram said the company was taking succession planning seriously, but had not yet approached anyone to replace Mr Martin. Mr Ingram also confirmed Elan will support the Deferno Trust,...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Market share of 20% targeted as sales of MS drug Tysabri continue to grow
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account